MX2016003265A - Composiciones nanoparticuladas para administracion dirigida de farmacos lipofilicos y farmacos lipofilicos labiles en medio acido para quimioterapias de cancer y su preparacion. - Google Patents
Composiciones nanoparticuladas para administracion dirigida de farmacos lipofilicos y farmacos lipofilicos labiles en medio acido para quimioterapias de cancer y su preparacion.Info
- Publication number
- MX2016003265A MX2016003265A MX2016003265A MX2016003265A MX2016003265A MX 2016003265 A MX2016003265 A MX 2016003265A MX 2016003265 A MX2016003265 A MX 2016003265A MX 2016003265 A MX2016003265 A MX 2016003265A MX 2016003265 A MX2016003265 A MX 2016003265A
- Authority
- MX
- Mexico
- Prior art keywords
- lipophilic
- prodrugs
- preparation
- acid labile
- targeted delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
En una modalidad, la presente solicitud describe nanopartículas de LDL sintéticas que comprenden mezclas de componentes seleccionados del grupo que consiste de fosfolípidos, triglicéridos, éster de colesterol y colesterol libre; que opcionalmente comprende además un agente seleccionado del grupo que consiste de antioxidantes naturales, ubiquinol y vitamina E y métodos para preparar las nanopartículas sintéticas. Las nanopartículas de LDL sintéticas descritas son capaces de suministrar selectivamente fármacos lipófilicos y profármacos de dianas celulares que expresan los receptores de LDL después de la inyección intravenosa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361877521P | 2013-09-13 | 2013-09-13 | |
PCT/US2014/055539 WO2015038993A1 (en) | 2013-09-13 | 2014-09-13 | Nanoparticulate compositions for targeted delivery of lipophilic drugs and acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016003265A true MX2016003265A (es) | 2016-06-07 |
Family
ID=51660029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016003265A MX2016003265A (es) | 2013-09-13 | 2014-09-13 | Composiciones nanoparticuladas para administracion dirigida de farmacos lipofilicos y farmacos lipofilicos labiles en medio acido para quimioterapias de cancer y su preparacion. |
Country Status (10)
Country | Link |
---|---|
US (3) | US9468603B2 (es) |
EP (1) | EP3043781A1 (es) |
JP (1) | JP2016530331A (es) |
KR (1) | KR20160055259A (es) |
CN (1) | CN105722506A (es) |
AU (1) | AU2014318471B2 (es) |
CA (1) | CA2922002A1 (es) |
MX (1) | MX2016003265A (es) |
SG (1) | SG11201601311VA (es) |
WO (1) | WO2015038993A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105722506A (zh) * | 2013-09-13 | 2016-06-29 | 阿伯疗法责任有限公司 | 用于癌症化学治疗剂的亲脂性药物和酸不稳定性亲脂性前体药物的靶向递送的纳米颗粒组合物及它们的制备 |
WO2018038253A1 (ja) * | 2016-08-26 | 2018-03-01 | 哲治 奥野 | 微小ナノ化薬剤およびその利用 |
JP7218949B2 (ja) * | 2018-04-16 | 2023-02-07 | チャンスー ヴィーケア ファーマテック カンパニー リミテッド | 抗凝固薬の即時放出医薬製剤及びその調製方法 |
US20230000815A1 (en) * | 2021-06-16 | 2023-01-05 | Veiled Therapeutics Llc | Acid-Labile Chemotherapeutic Compounds and Compositions |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6176414A (ja) * | 1984-09-21 | 1986-04-18 | Shionogi & Co Ltd | リポソーム製剤の製法 |
US6146659A (en) * | 1998-07-01 | 2000-11-14 | Neopharm, Inc. | Method of administering liposomal encapsulated taxane |
IL144756A0 (en) * | 1999-02-08 | 2002-06-30 | Alza Corp | Method for controlling liposome size |
CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
US20040213837A1 (en) * | 2002-08-05 | 2004-10-28 | Sankaram Mantripragada | Oil-core compositions for the sustained release of hydrophobic drugs |
US8252338B2 (en) * | 2005-11-10 | 2012-08-28 | The Regents Of The University Of California | Synthetic LDL as targeted drug delivery vehicle |
TWI376239B (en) * | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
CN101396343B (zh) * | 2007-09-26 | 2011-12-07 | 中国医学科学院药物研究所 | 以脂质复合物为中间载体的紫杉醇亚微乳 |
US20110077291A1 (en) * | 2009-09-30 | 2011-03-31 | Jianming Chen | Preparations of Taxanes for Intravenous Administration and the Preparation Method Thereof |
CN102048688B (zh) * | 2009-10-29 | 2014-03-05 | 中国医学科学院药物研究所 | 以胆固醇复合物为中间载体的紫杉醇亚微乳 |
CN101926757B (zh) | 2010-09-01 | 2013-01-02 | 北京大学 | 一种难溶性药物的液体组合物及其制备方法 |
JP5621071B2 (ja) * | 2011-06-06 | 2014-11-05 | アーバー・セラピューティクス・リミテッド・ライアビリティ・カンパニーArbor Therapeutics,LLC | 癌化学療法薬の酸に不安定で親油性のプロドラッグ |
US20140328759A1 (en) * | 2011-10-25 | 2014-11-06 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
KR20140048404A (ko) * | 2012-10-11 | 2014-04-24 | 포항공과대학교 산학협력단 | 저밀도 지단백질 유사 나노입자 및 이를 포함하는 간 표적 진단 및 치료용 조성물 |
US9889092B2 (en) * | 2013-03-13 | 2018-02-13 | The Board Of Regents Of The University Of Texas System | Low density lipoprotein nanocarriers for targeted delivery of omega-3 polyunsaturated fatty acids to cancer |
CN105722506A (zh) * | 2013-09-13 | 2016-06-29 | 阿伯疗法责任有限公司 | 用于癌症化学治疗剂的亲脂性药物和酸不稳定性亲脂性前体药物的靶向递送的纳米颗粒组合物及它们的制备 |
-
2014
- 2014-09-13 CN CN201480062013.XA patent/CN105722506A/zh active Pending
- 2014-09-13 JP JP2016542842A patent/JP2016530331A/ja active Pending
- 2014-09-13 WO PCT/US2014/055539 patent/WO2015038993A1/en active Application Filing
- 2014-09-13 CA CA2922002A patent/CA2922002A1/en not_active Abandoned
- 2014-09-13 US US14/485,713 patent/US9468603B2/en active Active
- 2014-09-13 AU AU2014318471A patent/AU2014318471B2/en not_active Ceased
- 2014-09-13 KR KR1020167009662A patent/KR20160055259A/ko not_active Application Discontinuation
- 2014-09-13 MX MX2016003265A patent/MX2016003265A/es unknown
- 2014-09-13 SG SG11201601311VA patent/SG11201601311VA/en unknown
- 2014-09-13 EP EP14780682.2A patent/EP3043781A1/en not_active Withdrawn
-
2016
- 2016-08-22 US US15/243,659 patent/US10064823B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 US US15/910,913 patent/US10369105B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
SG11201601311VA (en) | 2016-03-30 |
AU2014318471A1 (en) | 2016-03-10 |
JP2016530331A (ja) | 2016-09-29 |
KR20160055259A (ko) | 2016-05-17 |
AU2014318471B2 (en) | 2019-12-19 |
WO2015038993A1 (en) | 2015-03-19 |
CN105722506A (zh) | 2016-06-29 |
US20150079189A1 (en) | 2015-03-19 |
EP3043781A1 (en) | 2016-07-20 |
US10369105B2 (en) | 2019-08-06 |
US9468603B2 (en) | 2016-10-18 |
US20170042815A1 (en) | 2017-02-16 |
CA2922002A1 (en) | 2015-03-19 |
US20180235883A1 (en) | 2018-08-23 |
US10064823B2 (en) | 2018-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280771A (en) | Preparations of lipid nanoparticles and methods for administration of mRNA | |
PT3083556T (pt) | Lípidos e composições lipídicas para a entrega de agentes ativos | |
CY1120806T1 (el) | Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης | |
NZ712350A (en) | Abiraterone acetate formulation | |
MX2013008851A (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
IL245030A0 (en) | Lipid compositions for administration to messenger RNA | |
EP3268043A4 (en) | Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms | |
MX2016006896A (es) | Microcapsulas de lipidos que comprenden preferiblemente una substancia activa lipofilica y composicion que las contiene, su metodo de preparacion y su uso en dermatolgia y cosmetica. | |
SG11201408658PA (en) | Biodegradable drug delivery for hydrophobic compositions | |
PH12015501096A1 (en) | Composition for immediate and extended release | |
HUE041882T2 (hu) | Lipidek terápiás szer bevitelére szolgáló formulákhoz | |
MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
MX2012014079A (es) | Lipidos biodegradables para la administracion de agentes activos. | |
MX352907B (es) | Composiciones de un poliortoéster y un solvente aprótico. | |
MX2016003265A (es) | Composiciones nanoparticuladas para administracion dirigida de farmacos lipofilicos y farmacos lipofilicos labiles en medio acido para quimioterapias de cancer y su preparacion. | |
TN2014000322A1 (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
HK1223824A1 (zh) | 含有抗菌劑和抗炎劑的用於眼內給藥的藥劑組成 | |
WO2014134586A3 (en) | Injectable long-acting local anesthetic semi-solid formulations and its compostions | |
MY173692A (en) | Method for preparing drug-loaded amphiphilic copolymer micelle and composition thereof | |
BR132013025713F1 (pt) | composição farmacêutica antineoplásica de circulação prolongada e nanopartículas lipídicas sólidas contendo compostos nitroaromáticos | |
UA107508C2 (uk) | Жирова композиція для комбікормів |